info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Asia Pacific Cancer Biological Therapy Market Research Report Information: By Type (Monoclonal Antibodies, Interferons, Interleukins, Cancer Growth Inhibitors, Gene Therapy, Colony-Stimulating Factors, Targeted Therapy, Cancer Vaccines and others), By Phases (Phase I, Phase II, Phase III) By End Users (Hospitals & Clinics, Cancer Research Centers, Laboratories) - Forecast till 2032


ID: MRFR/Pharma/2980-HCR | 50 Pages | Author: Kinjoll Dey| November 2024

Asia Pacific Cancer Biological Therapy Market Overview 


Apac Cancer Biological Therapy Market Size was valued at USD 114.08 Billion in 2023. The Global Apac Cancer Biological Therapy industry is projected to grow from USD 124.30 Billion in 2024 to USD 246.95 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.23% during the forecast period (2024 - 2032).

Cancer is the leading and the second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and others.


Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. Various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor, such therapies known as; cancer targeted therapies.


The major driving factors for Asia Pacific cancer biological therapy market are increasing cancer survival rates, growing demand for advanced therapies such as biological therapy, growth of cancer healthcare facilities in emerging countries, etc. Additionally, less number of side effects associated with biological therapy as compared to conventional treatment methods is the critical growth factor. Conventional cancer treatment methods like chemotherapy, radiotherapy give effective result, but along with that these methods also show its counter effects on body. 


The side effects may include, loss of hair, weakened immune system, and such others depending upon the type, and phase of cancer. Biological therapies help to reduce the level of side effects as compared to other treatment methods. Biological therapies are giving the same amount of success rate for curing the cancer patient with 1st stage cancer approximately 27% to 35%. Owing to low level of side effects and high success rate of this therapy, the market is expected to grow rapidly. However, high cost of the treatment may restrain the market growth.


Asia Pacific Cancer Biological Therapy Market Key Players 


The leading market players in the Asia Pacific cancer biological therapy market include: 



  • Merck & Co., Inc. (US)

  • F. Hoffmann-La Roche Ltd (Switzerland)

  • Novartis AG (Switzerland)

  • Amgen Inc. (US)

  • Bristol-Myers Squibb (US)

  • Celgene (US)

  • Eli Lilly and Company (US)

  • EnGeneIC (Australia)

  • Pfizer (US)

  • Intas Pharmaceuticals Ltd. (India)

  • Sun Pharmaceutical Industries Ltd. (India)


Asia Pacific Cancer Biological Therapy Market Segmentation 


Asia Pacific cancer biological therapy market is segmented into types, phases, and end users.


On the basis of types the market is segmented into monoclonal antibodies, interferon, interleukins, cancer growth inhibitors, gene therapy, colony-stimulating factors, targeted therapy, cancer vaccines, and others. On the basis of phases, the market is segmented into phase I, phase II, and phase III.


On the basis of end users, the market is segmented into hospitals & clinics, cancer research centers, laboratories, and others.


Asia Pacific Cancer Biological Therapy Market Regional Analysis 


China dominates the Asia Pacific cancer biological therapy market owing to increasing prevalence of cancer.  Increasing adoption of smoking by people, rapid research & development and presence rapidly developing economy in this region fuel the growth of the market in Asia Pacific. Japan and Australia are other major contributor to the market growth in this region.


Intended Audience



  • Pharmaceutical Companies

  • Pharmaceutical Suppliers

  • Cancer Research Organizations

  • Potential Investors

  • Key Executive (CEO and COO) and Strategy Growth Manager

  • Research Companies

Report Attribute/Metric Details
Market Size USD 246.95 Billion by 2032
CAGR 9.23% (2024-2032)
Base Year   2021
Forecast Period   2024-2032
Historical Data   2020
Forecast Units   Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Types, end user, Region
Geographies Covered Asia Pacific
Key Vendors Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Amgen Inc. (US), Bristol-Myers Squibb (US), Celgene (US), Eli Lilly and Company (US), EnGeneIC (Australia), Pfizer (US), Intas Pharmaceuticals Ltd. (India), and Sun Pharmaceutical Industries Ltd. (India)


Frequently Asked Questions (FAQ) :

The projected CAGR of Asia Pacific Cancer Biological Therapy Market would 9.23% during the forecast period of 2024-2032.

The Asia Pacific Cancer Biological Therapy Market could be deterred by the high cost involved in the process.

The players are F. Hoffmann-La Roche Ltd (Switzerland), Merck & Co., Inc. (US), Bristol-Myers Squibb (US), Novartis AG (Switzerland), Amgen Inc. (US), Pfizer (US), Intas Pharmaceuticals Ltd. (India), Eli Lilly and Company (US), EnGeneIC (Australia), Celgene (US), and Sun Pharmaceutical Industries Ltd. (India).

Asia Pacific Cancer Biological Therapy Market segmented by types into interferon, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors, gene therapy, cancer vaccines, targeted therapy, and others.

Asia Pacific Cancer Biological Therapy Market segmented by end users into laboratories, cancer research centers, hospitals & clinics, and others.

Asia Pacific Cancer Biological Therapy Market

Asia Pacific cancer biological therapy market is expected to grow at a CAGR of 7.7% during the forecasted 2022-2030

Segmentation
By Type Monoclonal Antibodies Interferons Interleukins Cancer Growth Inhibitors Gene Therapy Colony-Stimulating Factors Targeted Therapy Cancer Vaccines
By Phases Phase I Phase II Phase III
By End Users Hospitals & Clinics Cancer Research Centers Laboratories
Key Players
Companies Profiled   Merck & Co.Inc. (US)   F. Hoffmann-La Roche Ltd (Switzerland)   Novartis AG (Switzerland)   Amgen Inc. (US)   Bristol-Myers Squibb (US)   Celgene (US)   Eli Lilly and Company (US)   EnGeneIC (Australia)   Pfizer (US)   Intas Pharmaceuticals Ltd. (India)   Sun Pharmaceutical Industries Ltd. (India)
Drivers
Market Driving Forces   increasing cancer survival rates   growing demand for advanced therapies such as biological therapy
Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.